BioSpace News Archive

Medicago today announced the publication of the results from the Phase 3 study of COVIFENZ®, COVID-19 vaccine (plant-based virus-like particles [VLP], recombinant, adjuvanted), in the New England Journal of Medicine (NEJM).

Phosplatin Therapeutics Inc. today announced that the Company has changed its name to Promontory Therapeutics Inc.

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 10:00 a.m. Pacific time.

Artiva Biotherapeutics, Inc. today announced the appointment of Edith A. Perez, M.D., as a member of the Company’s Board of Directors.

Metagenomi today announced that two presentations will be made at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, taking place virtually and in Washington, D.C., May 16-19, 2022.

Palisade Bio and co-development partner Newsoara Biopharma Co. Ltd, today announced they have received clearance from the National Medical Products Administration (NMPA) in China to proceed with their Phase 3 clinical trial to evaluate LB1148 for accelerated return of bowel function in adult patients undergoing bowel/abdominal surgery.

Biofrontera Inc. announced its sponsorship of the 17th Edition of the Music City Symposium for Cosmetic Advances & Laser Education, being held May 11-15, 2022 in Nashville, Tenn.

Anitoa systems, market leader in portable molecular testing, today announced the availability of an RT-PCR solution for testing dengue virus.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the Measurable residual disease Partnership and Alliance in Acute myeloid leukemia Clinical Treatment, is advancing efforts to establish measurable residual disease as a surrogate endpoint for overall survival in the treatment of acute myeloid leukemia.

Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Phase 3 SPOTLIGHT Study of Targeted PET Imaging Agent 18 F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer.